戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 r forms the basis for developing more potent active immunotherapy.
2 ight synergize with, rather than antagonize, active immunotherapy.
3 pecific antigen and an attractive target for active immunotherapy.
4 as (idiotype [Id]) can serve as a target for active immunotherapy.
5 on tumor cells is critical for the design of active immunotherapy.
6  responses and acts as a potent adjuvant for active immunotherapy.
7 splaying C3dg warrant further development as active immunotherapies.
8 enhance the function of DNA immunization for active immunotherapy, a panel of cytokines was added as
9 gents in breast cancer more effectively with active immunotherapy and potentially other anticancer th
10                      We hypothesized that an active immunotherapy approach targeting flk1 may inhibit
11 mmunotherapies, focusing on both passive and active immunotherapy approaches that have entered clinic
12 ced the therapeutic activity of adoptive and active immunotherapy, delaying tumor growth and prolongi
13 bulins, can serve as targets for passive and active immunotherapies for lymphoma.
14                               Animal models' active immunotherapies for melanoma show a requirement f
15                  Present clinical studies of active immunotherapy for malignancies using dendritic ce
16  To overcome this challenge, we developed an active immunotherapy for personalized treatment based on
17 ular immunization may enhance the effects of active immunotherapy for the treatment of synucleinopath
18 somers are potential compounds in developing active immunotherapy for treatment of VEGFR bearing tumo
19                    For more than 2 centuries active immunotherapy has been at the forefront of effort
20 ed clinically significant treatment effects, active immunotherapy has not yet become an established c
21 ide epitopes that can be used as targets for active immunotherapy have been identified within melanoc
22 ls, currently underway, evaluating antitumor active immunotherapies in patients with prostate cancer.
23 ergen exposure could provide a novel form of active immunotherapy in allergic diseases.
24 seful therapeutic agents in conjunction with active immunotherapy in cancer patients.
25 that when a Bcl-2 inhibitor is combined with active immunotherapy in humans, such as the use of a vac
26 ls has been used as a target for passive and active immunotherapy in patients with malignant melanoma
27 anced, nonviral genetic immunization for the active immunotherapy of cancer and indicated that using
28 ted targets that can serve as immunogens for active immunotherapy of cancer.
29  attractive alternative to vaccination-based active immunotherapy of melanoma.
30 fic TCR can serve as an effective target for active immunotherapy of T cell malignancies.
31 s could overcome some of the shortcomings of active immunotherapy or in vivo cytokine treatment, wher
32 hese results suggest that a longer period of active immunotherapy, or passive immunization, may be re
33 ch [idiotype (Id)] can serve as a target for active immunotherapy.Promising results have been obtaine
34 eted therapies, these successes suggest that active immunotherapy represents a path to obtain a durab
35                                              Active immunotherapy strategies currently under developm
36 specific CTLs or to develop antigen-specific active immunotherapy strategies for glioma patients.
37 r conditions acceptable for use in adjuvant, active immunotherapy strategies for surgically treated m
38 nstrate for the first time the ability of an active immunotherapy strategy to generate antigen-specif
39 decades following the introduction of highly active immunotherapies such as rituximab.
40                                              Active immunotherapies, such as vaccines and immune chec
41 hat the brain is not a barrier to successful active immunotherapy that uses gene-modified autologous
42 tion, antibiotics, and, recently, the use of active immunotherapy to enhance the immune response towa
43                                        After active immunotherapy, we detected TRP-2-specific cytotox
44  assemblies were investigated as therapeutic active immunotherapies, which may offer advantages over
45 mmunotherapy of CRC patients with mAb and in active immunotherapy with anti-idiotypic Abs mimicking t
46 erved in patients who received postoperative active immunotherapy with Canvaxin therapeutic cancer va
47                                              Active immunotherapy with conformational B cell epitopes
48                                 Furthermore, active immunotherapy with recombinant YF viruses induced
49 on clinical outcome in patients who received active immunotherapy with tumor antigen vaccines.
50                                              Active immunotherapy with vaccines has the potential to